Compositions and methods for treating hematological cancers targeting the SIRPα CD47 interaction
US10907209B2 · kind B2 · utility
4Cited by
11References
42Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | May 14, 2010 |
| Grant date | Feb 2, 2021 |
| Priority date | — |
| Expiry date | Jul 29, 2032 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Q2600/156
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to modulating the SIRPα-CD47 interaction in order to treat hematological cancer and compounds therefor. In some embodiments, there is provided methods and uses of SIRPα polypeptides, fragments and fusion proteins for treating hematological cancer, preferably human acute myeloid leukemia.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.